Who is responsible for an NMPA medical-device registration application?

The device-registration applicant is responsible for the finished device, its submission and the truthfulness of the supporting information. BIO can coordinate material and project information but does not replace the applicant or guarantee review outcomes.

Do raw-material documents prove finished-device compliance?

No. Supplier documents can support a device dossier, but the applicant must evaluate the finished device in its intended design, manufacturing, sterilization and use context.

What can BIO support in a China market-access project?

BIO can help with application and account screening, document-list and gap coordination, technical communication, samples and local-supply coordination. Scope is confirmed for each project.

Can a medical-device master file be referenced?

A master file may be referenced when it is applicable, registered and authorized for the specific application. Voluntary master-file registration and its receipt do not constitute device approval, and the applicant retains responsibility.

What determines the evidence plan for a silicone-containing device?

The plan depends on device classification, intended use, design, contact type and duration, manufacturing and sterilization, risk management and applicable rules or guidance. It cannot be inferred from a material label alone.

China Market Access

Navigate China's medical device market with confidence

BIO supports application screening, document coordination, technical communication, samples and local-supply planning for medical-material projects in China. The device applicant remains responsible for finished-device evidence and registration.

Market Access Is Not Shipping

Regulated markets reward local understanding

Entering China's regulated medical device market requires application mapping, technical trust, documentation readiness, and strategic customer development — not simply moving products across a border.

Responsibilities and evidence hand-offs for a medical-material project entering China's device-registration pathway — BIO original editorial evidence map. Supplier documents and BIO coordination can support a project; they do not replace the applicant's finished-device evidence or NMPA review. General responsibilities only, not legal advice or a registration guarantee. Sources [1–3].

Core boundary: Material identity, specifications and available supplier files are inputs. The device applicant still owns classification, risk management, product requirements, nonclinical or clinical evidence, quality-system obligations and the submission.

China Market Mapping

Where your material fits

We organize candidate device segments and accounts around the material's documented capabilities, intended application and project readiness. Priority is project-specific and is not inferred from an unsupported regional market map.

Medical device innovators
Listed device companies
Specialized implantable device manufacturers
Research hospitals and institutes
Emerging neurotech and cardiac device companies

What the screening map means

It is a working list of applications, candidate accounts, decision roles, documentation needs and next evidence steps.

What it does not mean

It does not claim that a region is larger, that an account is qualified, or that a material is suitable before current documentation and project evidence are reviewed.

Application Prioritization

Focus where your material creates value

Long-term implantable devices

High-reliability, biocompatible material requirements.

Cochlear implants

Sealing, encapsulation, and durability over device lifetime.

Neurostimulation

Neural interfaces and emerging neurotechnology platforms.

Cardiac devices

Leads, connectors, and heart-assist components.

Gastrointestinal stents

Stent components, coatings, and delivery systems.

Catheters & wearables

Tubing, bonding, and patient-facing applications.

From Opportunity to Design-in

A clear pathway to adoption

Market Scan

Segment the landscape and size the opportunity.

Target Account List

Prioritize accounts by fit and readiness.

Technical Introduction

Engage R&D, engineering, and QA teams.

Sample Evaluation

Support testing and material assessment.

Validation Support

Align on requirements and documentation.

Commercial Account

Develop and scale long-term adoption.

Market Intelligence Capabilities

Decision-ready, execution-focused

Account Segmentation

By application, stage, regulatory sensitivity, and readiness.

Design-in Pipeline

Track progress from discovery to commercial adoption.

Competitive Signals

Monitor competitive movement and material substitution risk.

Regulatory Status Tracking

Follow regulatory status relevant to your applications.

Regulatory Source Map

Responsibilities and evidence boundaries

SAMR Measures for Medical Device Registration and Filing: device classification, applicant responsibility, safety, effectiveness, quality control and submission requirements.
NMPA domestic Class III first-registration service guide: submission modules and acceptance boundary. See also the English registration-provisions overview.
Medical-device master-file notice: voluntary registration and reference mechanism; a filing receipt is not approval and the device applicant retains responsibility.
ISO 10993-1:2025: biological evaluation within risk management for the particular device use context.

General information only; not legal advice. Requirements vary with device classification, intended use, design and the rules or guidance in force for the project.

Discuss your China market access plan

Turn China market signals into commercial action with a partner built for regulated medical materials.

Talk to BIO